Kyverna Reports Deep, Durable Phase 2 Data for Miv-cel in Myasthenia Gravis, Reinforcing Phase 3 Confidence
KYTX has more than doubled off its 52-week low of $1.78.
Summary
Kyverna Therapeutics announced exceptionally strong longer-term Phase 2 data for its miv-cel therapy in generalized myasthenia gravis, showing 100% patient response and durable, drug-free remission potential.
Key Events · Product Development and Regulatory · KYTX
-
Positive Longer-Term Phase 2 Data
Miv-cel demonstrated deep and durable clinical responses in 100% of generalized myasthenia gravis patients, with sustained benefits observed out to one year.
-
Strong Efficacy and Safety Profile
Patients achieved rapid and robust reductions in MG-ADL and QMG scores, with 57% reaching minimal symptom expression. The therapy was well-tolerated with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) events.
-
Reinforces Phase 3 Confidence
The data strengthens conviction in miv-cel's differentiated profile and the ongoing Phase 3 registrational trial, supporting its potential for durable, drug-free remission.
-
Conference Call Scheduled
The company will host a conference call on April 22, 2026, to discuss these results and updated data for stiff person syndrome.
Analysis · KYTX · Life Sciences
This 8-K announces highly positive longer-term Phase 2 data for Kyverna's lead CAR T-cell therapy, miv-cel, in generalized myasthenia gravis (gMG). The reported 100% patient response rate with rapid, sustained, and durable improvements in key clinical measures (MG-ADL, QMG) out to 52 weeks, coupled with a favorable safety profile and the ability to achieve drug-free remission, significantly de-risks the ongoing Phase 3 registrational trial. These results strengthen miv-cel's potential as a best-in-class treatment and are a major catalyst for the company's neuroimmunology franchise.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 39.1% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYTX was trading at $9.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $600.2M. The 52-week trading range was $1.78 to $13.67. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.